Marker Therapeutics, Inc

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Markers unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. Once infused into patients, this population of multiTAA-specific T cells attacks multiple tumor targets and acts to activate the patients immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based...

Immunotherapy and t cell based therapies

Marker therapeutics, inc operates in the Pharmaceutical manufacturing industry.

Marker therapeutics, inc's revenue is 1m - 10m

Marker therapeutics, inc has 11 - 50 employees.